Signal2026-06-25
ClinicalTrials.gov

[PHASE1] Evaluation of the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of BBM-C101 Injection in Patients With Cervical High-Grade Squamous Intraepithelial Lesion(HSIL)

Part of

Enhancing Dendritic Cell Antitumor Function

Open primary sourceSee the whole picture